Collaboration and licensing agreement

Sinclair IS Pharma Signs 10-year Partnership with Hikma to Commercialise Flammacerium in MENA Region

LONDON - March 18, 2013 - Sinclair IS Pharma (AIM:SPH.L) ("Sinclair IS" or the "Group"), the international specialty pharma company, and Hikma Pharmaceuticals PLC ("Hikma") (LSE:HIK) (NASDAQ Dubai: HIK) today announce the signing of an exclusive 10-year collaboration and licensing agreement for Hikma to commercialise Flammacerium, Sinclair's leading hospital product for the prevention and treatment of infections from severe burn wounds, in the Middle East and North Africa ("MENA") region.

Under the collaboration agreement, Hikma will be Sinclair's exclusive partner for Flammacerium in eighteen countries within the MENA region and will be responsible for registering and commercialising the product with first launches expected late 2014/early 2015. 

"This collaboration further demonstrates Sinclair's ability to move our product portfolio into fast-growing, emerging markets through key regional partnerships," said Chris Spooner, Chief Executive Officer, Sinclair IS Pharma. "Hikma's presence and reputation across the MENA region will enable us to rapidly progress the adoption of Flammacerium, a key growth component of our strategic Flamma franchise."

Ends

For further information please contact:

Sinclair IS Pharma plc Tel: +44 (0) 20 7467 6920

Chris Spooner

Alan Olby

Robert Taylor

Peel Hunt LLP Tel: +44 (0) 20 7418 8900

James Steel

Vijay Barathan 

Notes to Editors:

About Sinclair IS Pharma plc - www.sinclairispharma.com 

Sinclair IS Pharma is an international specialty pharmaceutical company centred on Dermatology; in particular Aesthetics, Wound care, and Skin care. The group has a direct sales and marketing presence in the top five European markets and a rapidly growing International division concentrated on the Emerging Markets through long term multi-product, multi-country, sales, marketing and distribution deals with key strategic partners.